McDonnell Genome Institute

10x Genomics Launches Xenium Catalyst Network

Retrieved on: 
Wednesday, December 20, 2023

PLEASANTON, Calif., Dec. 20, 2023 /PRNewswire/ -- 10x Genomics, Inc., (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data for researchers worldwide. The four founding members of the Xenium Catalyst Network will add significant capacity for the company's Xenium Catalyst Program, a technical access service launched earlier this year for prospective customers.

Key Points: 
  • The four founding members of the Xenium Catalyst Network will add significant capacity for the company's Xenium Catalyst Program, a technical access service launched earlier this year for prospective customers.
  • 10x Genomics expects to add more research institutions to the Xenium Catalyst Network in 2024.
  • "K2bio, a novel full service preclinical Contract Research Organization (CRO), welcomes our partnership with 10x Genomics and the Xenium Catalyst Network," said Kieron Jones, CEO at K2bio.
  • "Participating in the 10x Genomics Xenium Catalyst Network will help us deliver state-of-the-art spatial genomics services," stated Michael Heinz, Director of Research Operations at the McDonnell Genome Institute.

Oxford Nanopore Technologies and Fabric Genomics Collaborate to Launch an Integrated Whole-Genome Sequencing Solution to Advance the Future of Paediatric Patient Care

Retrieved on: 
Tuesday, October 31, 2023

It is estimated that roughly 2.8 million children in the US reported a rare genetic disorder, according to data from the National Survey of Children’s Health .

Key Points: 
  • It is estimated that roughly 2.8 million children in the US reported a rare genetic disorder, according to data from the National Survey of Children’s Health .
  • "For this incredibly high-risk patient population, speed and data-rich insights matter,” said Gordon Sanghera, PhD, CEO of Oxford Nanopore Technologies.
  • Fabric Genomics and Rady Children’s Institute for Genomic Medicine have published results showing Fabric AI GEM to predict causative variants in genomes from previously diagnosed newborns and rare disease patients.
  • In addition, the partners will launch early customer availability at the meeting and showcase a workflow integration at Fabric Genomic’s booth #1215 on Friday November 3rd at 1 p.m.

OmniTier Unveils the Industry's First On-Premise, Standalone, End-To-End Genomic Analysis Appliance, at Cost Below $50 Per WGS Sample, at Scale

Retrieved on: 
Tuesday, April 18, 2023

SAN JOSE, Calif., April 18, 2023 /PRNewswire/ -- OmniTier Inc, a leader in on-premise genomics analysis products, today launched the industry's first on-premise, standalone appliance for both human genomic data analysis (secondary analysis) and biomedical data interpretation (tertiary analysis), called CompStor Spectrum™. Benefitting from proprietary AI, acceleration technology and built-in automation, CompStor Spectrum™ can produce high volume genomics test reports at an average cost per whole genome sequencing (WGS) analysis of less than $50 each.

Key Points: 
  • Benefitting from proprietary AI, acceleration technology and built-in automation, CompStor Spectrum™ can produce high volume genomics test reports at an average cost per whole genome sequencing (WGS) analysis of less than $50 each.
  • Research and clinical organizations, and genomic services providers can benefit from CompStor Spectrum™ by achieving large cost savings, from automated end-to-end sample analysis, and increased data security from on-premise or private cloud deployments.
  • OmniTier genomic analysis appliances are installed in an organization's own IT data center and operated by bioinformaticians or geneticists through their local browser.
  • "CompStor® Spectrum is designed to complement the cost reduction in sample costs announced by sequencer suppliers, to make WGS and WES analysis and testing more affordable."

PLEXIUM STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF DANIEL SIPES AS SENIOR VICE PRESIDENT, HEAD OF TECHNOLOGY

Retrieved on: 
Wednesday, August 24, 2022

SAN DIEGO, Aug. 24, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology.

Key Points: 
  • SAN DIEGO, Aug. 24, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology.
  • Mr. Sipes brings over two decades of experience in developing and implementing new technologies for drug discovery to Plexium, with a focus on next-generation high throughput screening and novel assay development.
  • "We are confident that he will lead our teams toward success and help us make significant breakthroughs for patients in the field of Targeted Protein Degradation."
  • Prior to Strateos, he was Director, Advanced Automation Technologies at the Genomics Institute of the Novartis Research Foundation (GNF).

Dalrada Financial Corporation Appoints Professor Elizabeth Winzeler to Healthcare Advisory Board

Retrieved on: 
Thursday, June 23, 2022

Dalrada Financial Corporation (OTCQB: DFCO , Dalrada Financial Corporation, "Dalrada") today announced the appointment of Elizabeth Ann Winzeler, Ph.D., a Professor in the Department of Pediatrics at the University of California, San Diego, School of Medicine, as a member of the Dalrada Health advisory board.

Key Points: 
  • Dalrada Financial Corporation (OTCQB: DFCO , Dalrada Financial Corporation, "Dalrada") today announced the appointment of Elizabeth Ann Winzeler, Ph.D., a Professor in the Department of Pediatrics at the University of California, San Diego, School of Medicine, as a member of the Dalrada Health advisory board.
  • The group is composed of distinguished life sciences industry leaders whose industry knowledge and guidance are intended to accelerate Dalrada Healths national healthcare model.
  • Dalrada Financial Corporation and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets.
  • Established in 1982, Dalrada has since grown its footprint to include the unique business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies.

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies

Retrieved on: 
Thursday, June 2, 2022

Ingelheim, Germany and Singapore, June 2, 2022 - (ACN Newswire) - Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Key Points: 
  • Ingelheim, Germany and Singapore, June 2, 2022 - (ACN Newswire) - Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.
  • Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.
  • Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies).
  • Under the terms of the agreement, Boehringer Ingelheim will be responsible for further research, preclinical and clinical development as well as commercialization of targeted cancer therapies using the antibodies from A*STAR.

BC Platforms Drives Data Enablement and Collaboration to Accelerate Precision Medicine in Asia

Retrieved on: 
Monday, June 6, 2022

It is part of BCP's efforts to support the growth of precision medicine activities in Asia Pacific.

Key Points: 
  • It is part of BCP's efforts to support the growth of precision medicine activities in Asia Pacific.
  • Today, real-world data generated from Asian countries is not represented well enough and data diversity is key to solving the most pressing research questions," said Mr Tero Silvola, Chief Executive Officer of BC Platforms.
  • This highly visible partnership is part of BC Platforms' rapidly growing data partner network for secure and regulatory compliant sharing of real-world data.
  • BC Platforms is a global leader in providing a powerful data and technology platform for personalised medicine and drug development, accelerating the translation of insights into clinical practice.

BC Platforms Drives Data Enablement and Collaboration to Accelerate Precision Medicine in Asia

Retrieved on: 
Monday, June 6, 2022

It is part of BCP's efforts to support the growth of precision medicine activities in Asia Pacific.

Key Points: 
  • It is part of BCP's efforts to support the growth of precision medicine activities in Asia Pacific.
  • Today, real-world data generated from Asian countries is not represented well enough and data diversity is key to solving the most pressing research questions," said Mr Tero Silvola, Chief Executive Officer of BC Platforms.
  • This highly visible partnership is part of BC Platforms' rapidly growing data partner network for secure and regulatory compliant sharing of real-world data.
  • BC Platforms is a global leader in providing a powerful data and technology platform for personalised medicine and drug development, accelerating the translation of insights into clinical practice.

Panoramic Atlases of Life Published in Cell Mark Establishment of SpatioTemporal Omics Consortium

Retrieved on: 
Thursday, May 5, 2022

SHENZHEN, China, May 5, 2022 /PRNewswire/ -- Scientists from 16 countries today announced the establishment of the SpatioTemporal Omics Consortium (STOC), an open scientific community focused on using spatially resolved cellular resolution omics technology to map and understand life. Their first studies resulted in state-of-the-art panoramic spatial atlases of life, published in Cell and Developmental Cell on May 4.

Key Points: 
  • Their first studies resulted in state-of-the-art panoramic spatial atlases of life, published in Cell and Developmental Cell on May 4.
  • "In the last few years, there has been a lot of progress of mapping the genome and transcriptome in single cells.
  • The transformational aspects of spatiotemporal omics for scientific research are captured in the goals of the STOC, as Weibin Liu, STOC Organizing Committee Member, explains.
  • "They lay the groundwork for multiple atlases the Consortium could complete together, and they validate approaches for creating other spatiotemporal atlases."

Panoramic Atlases of Life Published in Cell Mark Establishment of SpatioTemporal Omics Consortium

Retrieved on: 
Thursday, May 5, 2022

SHENZHEN, China, May 5, 2022 /PRNewswire/ -- Scientists from 16 countries today announced the establishment of the SpatioTemporal Omics Consortium (STOC), an open scientific community focused on using spatially resolved cellular resolution omics technology to map and understand life. Their first studies resulted in state-of-the-art panoramic spatial atlases of life, published in Cell and Developmental Cell on May 4.

Key Points: 
  • Their first studies resulted in state-of-the-art panoramic spatial atlases of life, published in Cell and Developmental Cell on May 4.
  • "In the last few years, there has been a lot of progress of mapping the genome and transcriptome in single cells.
  • The transformational aspects of spatiotemporal omics for scientific research are captured in the goals of the STOC, as Weibin Liu, STOC Organizing Committee Member, explains.
  • "They lay the groundwork for multiple atlases the Consortium could complete together, and they validate approaches for creating other spatiotemporal atlases."